Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

One Arm, Exploratory Study of Tislelizumab Combined With Anlotinib and 2-cycle Irinotecan Monotherapy as Second Treatment of Small Cell Lung Cancer

NCT05027100 is registered in ClinicalTrials.gov with Haibo Zhang as lead sponsor.

NCT NCT05027100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05027100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
One Arm, Exploratory Study of Tislelizumab Combined With Anlotinib and 2-cycle Irinotecan Monotherapy as Second Treatment of Small Cell Lung Cancer
Lead sponsor
Haibo Zhang
Phase
Not applicable
Overall status
Unknown status
Start date
September 30, 2021
Completion date
June 30, 2023
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer (sclc)